Evidence map›Paper›PMID 35742384›Full record

ArticleInternational journal of environmental research and public health2022

Risk Measurement of Perinatal and Neonatal Morbidity Characteristics and Applicability of GAIA Case Definitions: Results and Lessons Learnt of a Hospital-Based Prospective Cohort Study in the Valencia Region (2019-2020).

Antonio Carmona, María Latorre Tejerina, Alicia Martínez Sebastián, Dafina Dobreva, Cristina P Jurca, Sergio Huerta Barberá, Vicente Bernat Montoya, Mercedes Aristoy Zabaleta, Ana Pineda Caplliure, Beatriz Mansilla Roig and 5 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Antonio CarmonaVaccines Research Department, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fisabio), Av. de Catalunya, 21, 46020 Valencia, Spain.
María Latorre TejerinaDepartment of Pediatrics, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004 Castelló de la Plana, Spain.
Alicia Martínez SebastiánDepartment of Pediatrics, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar, 90, 46017 Valencia, Spain.
Dafina DobrevaP95 Pharmacovigilance and Epidemiology, 3010 Leuven, Belgium.
Cristina P JurcaDepartment of Pediatrics, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004 Castelló de la Plana, Spain.
Sergio Huerta BarberáDepartment of Pediatrics, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004 Castelló de la Plana, Spain.
Vicente Bernat MontoyaDepartment of Pediatrics, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004 Castelló de la Plana, Spain.
Mercedes Aristoy ZabaletaDepartment of Pediatrics, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004 Castelló de la Plana, Spain.
Ana Pineda CaplliureDepartment of Pediatrics, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar, 90, 46017 Valencia, Spain.
Beatriz Mansilla RoigDepartment of Pediatrics, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar, 90, 46017 Valencia, Spain.ORCID 0000-0001-7414-6115
María Navío AnayaDepartment of Pediatrics, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar, 90, 46017 Valencia, Spain.
Ricardo Tosca-SeguraDepartment of Pediatrics, Hospital General Universitario de Castellón, Avinguda de Benicàssim, 128, 12004 Castelló de la Plana, Spain.
Miguel Tortajada-GirbésDepartment of Pediatrics, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar, 90, 46017 Valencia, Spain.
Javier Díez-DomingoVaccines Research Department, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fisabio), Av. de Catalunya, 21, 46020 Valencia, Spain.ORCID 0000-0003-1008-3922
Alejandro Orrico-SánchezVaccines Research Department, Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fisabio), Av. de Catalunya, 21, 46020 Valencia, Spain.ORCID 0000-0002-3780-3187

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-marketing safety surveillance of new vaccines aimed to be administered during pregnancy is crucial to orchestrate efficient adverse events evaluation. This is of special relevance in the current landscape of new vaccines being introduced in the pregnant women population, and particularly due to the recent administration of COVID-19 vaccines in pregnant women. This multi-center prospective cohort study, nested within the WHO-Global Vaccine Safety-MCC study, involved two hospitals in the Valencia region. Hereby, the incidence rates of seven perinatal and neonatal outcomes in the Valencia region are presented. The pooled data analysis of the two Valencian hospitals allowed the estimation of incidence rates in the Valencia Region (per 1000 live births): 86.7 for low birth weight, 78.2 for preterm birth, 58.8 for small for gestational age, 13 for congenital microcephaly, 0.4 for stillbirth, 1.2 for neonatal death and 6.5 for neonatal infection. These figures are in line with what is expected from a high-income country and the previously reported rates for Spain and Europe, except for the significantly increased rate for congenital microcephaly. Regarding the data for maternal immunization, the vaccination status was collected for 94.4% of the screened pregnant women, highlighting the high quality of the Valencian Vaccine Registry. The study also assessed the Valencian hospitals' capacity for identifying and collecting data on maternal immunization status, as well as the applicability of the GAIA definitions to the identified outcomes.

Indexed as

COVID-19MicrocephalyPremature BirthVaccinesAdolescentCOVID-19 VaccinesFemaleHospitalsHumansInfant, NewbornMorbidityPregnancyPregnancy OutcomeProspective StudiesCOVID-19 VaccinesVaccinesincidence ratesmaternal immunizationneonatal outcomespregnancystandardized case definitionsvaccinationvaccine safety

Identifiers

PMID35742384
PMCPMC9223180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.